Norway Androgenetic Alopecia Market Size & Outlook
Norway androgenetic alopecia market, 2018-2030 (US$M)
Related Markets
Norway androgenetic alopecia market highlights
- The Norway androgenetic alopecia market generated a revenue of USD 8.1 million in 2023 and is expected to reach USD 13.2 million by 2030.
- The Norway market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
- In terms of segment, pharmaceuticals was the largest revenue generating treatment in 2023.
- Devices is the most lucrative treatment segment registering the fastest growth during the forecast period.
Androgenetic alopecia market data book summary
| Market revenue in 2023 | USD 8.1 million |
| Market revenue in 2030 | USD 13.2 million |
| Growth rate | 7.2% (CAGR from 2023 to 2030) |
| Largest segment | Pharmaceuticals |
| Fastest growing segment | Devices |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pharmaceuticals, Devices |
| Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
Other key industry trends
- In terms of revenue, Norway accounted for 0.3% of the global androgenetic alopecia market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany androgenetic alopecia market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 181.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Androgenetic Alopecia Market Scope
Androgenetic Alopecia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway androgenetic alopecia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to androgenetic alopecia market will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.77% in 2023. Horizon Databook has segmented the Norway androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing geriatric population in the country is boosting the prevalence of disease, which is creating new opportunities for key stakeholders. According to the World Bank data, in 2022, the overall population aged 65 & above in Norway was around 1 million, and it is expected to increase in the coming decade.
Global companies are entering and expanding their reach into the Norway’s androgenetic alopecia market to capitalize on the lucrative opportunities. Companies such as Merck & Co., Inc., FOLIGAIN LLC, Johnson & Johnson Services, Inc., Perrigo Company plc, Fotona, Curallux, LLC, and others, offer pharmaceutical drugs or low-level light therapy devices for AGA in the country.
Reasons to subscribe to Norway androgenetic alopecia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway androgenetic alopecia market databook
-
Our clientele includes a mix of androgenetic alopecia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway androgenetic alopecia market , including forecasts for subscribers. This country databook contains high-level insights into Norway androgenetic alopecia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway androgenetic alopecia market size, by treatment, 2018-2030 (US$M)
Norway Androgenetic Alopecia Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
